<?xml version='1.0' encoding='utf-8'?>
<document id="22515360"><sentence text="Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori." /><sentence text=" Classical second-line anti-Helicobacter pylori includes proton-pump inhibitor, tetracycline, metronidazole, and bismuth salts, but alternative therapies are required owing to the restricted availability of the latter"><entity charOffset="80-92" id="DDI-PubMed.22515360.s2.e0" text="tetracycline" /><entity charOffset="94-107" id="DDI-PubMed.22515360.s2.e1" text="metronidazole" /><entity charOffset="113-120" id="DDI-PubMed.22515360.s2.e2" text="bismuth" /><pair ddi="false" e1="DDI-PubMed.22515360.s2.e0" e2="DDI-PubMed.22515360.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22515360.s2.e0" e2="DDI-PubMed.22515360.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22515360.s2.e0" e2="DDI-PubMed.22515360.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22515360.s2.e1" e2="DDI-PubMed.22515360.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22515360.s2.e1" e2="DDI-PubMed.22515360.s2.e2" /></sentence><sentence text=" Levofloxacin-containing triple therapy is recommended but is expensive"><entity charOffset="1-13" id="DDI-PubMed.22515360.s3.e0" text="Levofloxacin" /></sentence><sentence text=" Besides, quinolone resistance in an endemic tuberculosis infection area like Taiwan is concerned"><entity charOffset="10-19" id="DDI-PubMed.22515360.s4.e0" text="quinolone" /></sentence><sentence text=" The low in vitro antibiotic resistance to amoxicillin and tetracycline in Taiwanese H"><entity charOffset="43-54" id="DDI-PubMed.22515360.s5.e0" text="amoxicillin" /><entity charOffset="59-71" id="DDI-PubMed.22515360.s5.e1" text="tetracycline" /><pair ddi="false" e1="DDI-PubMed.22515360.s5.e0" e2="DDI-PubMed.22515360.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22515360.s5.e0" e2="DDI-PubMed.22515360.s5.e1" /></sentence><sentence text=" pylori strains implies that in vivo esomeprazole/amoxicillin/tetracycline (EAT) second-line rescue therapy may be effective"><entity charOffset="37-49" id="DDI-PubMed.22515360.s6.e0" text="esomeprazole" /><entity charOffset="50-61" id="DDI-PubMed.22515360.s6.e1" text="amoxicillin" /><entity charOffset="62-74" id="DDI-PubMed.22515360.s6.e2" text="tetracycline" /><entity charOffset="76-79" id="DDI-PubMed.22515360.s6.e3" text="EAT" /><pair ddi="false" e1="DDI-PubMed.22515360.s6.e0" e2="DDI-PubMed.22515360.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22515360.s6.e0" e2="DDI-PubMed.22515360.s6.e1" /><pair ddi="false" e1="DDI-PubMed.22515360.s6.e0" e2="DDI-PubMed.22515360.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22515360.s6.e0" e2="DDI-PubMed.22515360.s6.e3" /><pair ddi="false" e1="DDI-PubMed.22515360.s6.e1" e2="DDI-PubMed.22515360.s6.e1" /><pair ddi="false" e1="DDI-PubMed.22515360.s6.e1" e2="DDI-PubMed.22515360.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22515360.s6.e1" e2="DDI-PubMed.22515360.s6.e3" /><pair ddi="false" e1="DDI-PubMed.22515360.s6.e2" e2="DDI-PubMed.22515360.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22515360.s6.e2" e2="DDI-PubMed.22515360.s6.e3" /></sentence><sentence text=" This study compared the efficacy of esomeprazole/amoxicillin/levofloxacin (EAL) and EAT second-line eradication therapies and determines the clinical factors influencing the efficacy of salvage regimens"><entity charOffset="37-49" id="DDI-PubMed.22515360.s7.e0" text="esomeprazole" /><entity charOffset="50-61" id="DDI-PubMed.22515360.s7.e1" text="amoxicillin" /><entity charOffset="62-74" id="DDI-PubMed.22515360.s7.e2" text="levofloxacin" /><entity charOffset="76-79" id="DDI-PubMed.22515360.s7.e3" text="EAL" /><entity charOffset="85-87" id="DDI-PubMed.22515360.s7.e4" text="EAT" /><pair ddi="false" e1="DDI-PubMed.22515360.s7.e0" e2="DDI-PubMed.22515360.s7.e0" /><pair ddi="false" e1="DDI-PubMed.22515360.s7.e0" e2="DDI-PubMed.22515360.s7.e1" /><pair ddi="false" e1="DDI-PubMed.22515360.s7.e0" e2="DDI-PubMed.22515360.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22515360.s7.e0" e2="DDI-PubMed.22515360.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22515360.s7.e0" e2="DDI-PubMed.22515360.s7.e4" /><pair ddi="false" e1="DDI-PubMed.22515360.s7.e1" e2="DDI-PubMed.22515360.s7.e1" /><pair ddi="false" e1="DDI-PubMed.22515360.s7.e1" e2="DDI-PubMed.22515360.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22515360.s7.e1" e2="DDI-PubMed.22515360.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22515360.s7.e1" e2="DDI-PubMed.22515360.s7.e4" /><pair ddi="false" e1="DDI-PubMed.22515360.s7.e2" e2="DDI-PubMed.22515360.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22515360.s7.e2" e2="DDI-PubMed.22515360.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22515360.s7.e2" e2="DDI-PubMed.22515360.s7.e4" /><pair ddi="false" e1="DDI-PubMed.22515360.s7.e3" e2="DDI-PubMed.22515360.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22515360.s7.e3" e2="DDI-PubMed.22515360.s7.e4" /></sentence><sentence text="" /><sentence text="One hundred and twenty-eight patients who failed H" /><sentence text=" pylori eradication using the standard triple therapy for 7 days are randomly assigned to either EAL group (esomeprazole 40 mg twice daily, amoxicillin 1 g twice daily, and levofloxacin 500 mg once daily) for 7 days or EAT group (esomeprazole 40 mg twice daily, amoxicillin 1 g twice daily, tetracycline 500 mg four times daily) for 14 days"><entity charOffset="108-120" id="DDI-PubMed.22515360.s10.e0" text="esomeprazole" /><entity charOffset="140-151" id="DDI-PubMed.22515360.s10.e1" text="amoxicillin" /><entity charOffset="173-185" id="DDI-PubMed.22515360.s10.e2" text="levofloxacin" /><entity charOffset="219-222" id="DDI-PubMed.22515360.s10.e3" text="EAT" /><entity charOffset="230-242" id="DDI-PubMed.22515360.s10.e4" text="esomeprazole" /><entity charOffset="262-273" id="DDI-PubMed.22515360.s10.e5" text="amoxicillin" /><entity charOffset="291-303" id="DDI-PubMed.22515360.s10.e6" text="tetracycline" /><entity charOffset="97-108" id="DDI-PubMed.22515360.s10.e7" text="EAL" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e7" e2="DDI-PubMed.22515360.s10.e7" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e7" e2="DDI-PubMed.22515360.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e7" e2="DDI-PubMed.22515360.s10.e1" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e7" e2="DDI-PubMed.22515360.s10.e2" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e7" e2="DDI-PubMed.22515360.s10.e3" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e7" e2="DDI-PubMed.22515360.s10.e4" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e7" e2="DDI-PubMed.22515360.s10.e5" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e7" e2="DDI-PubMed.22515360.s10.e6" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e0" e2="DDI-PubMed.22515360.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e0" e2="DDI-PubMed.22515360.s10.e1" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e0" e2="DDI-PubMed.22515360.s10.e2" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e0" e2="DDI-PubMed.22515360.s10.e3" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e0" e2="DDI-PubMed.22515360.s10.e4" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e0" e2="DDI-PubMed.22515360.s10.e5" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e0" e2="DDI-PubMed.22515360.s10.e6" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e1" e2="DDI-PubMed.22515360.s10.e1" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e1" e2="DDI-PubMed.22515360.s10.e2" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e1" e2="DDI-PubMed.22515360.s10.e3" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e1" e2="DDI-PubMed.22515360.s10.e4" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e1" e2="DDI-PubMed.22515360.s10.e5" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e1" e2="DDI-PubMed.22515360.s10.e6" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e2" e2="DDI-PubMed.22515360.s10.e2" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e2" e2="DDI-PubMed.22515360.s10.e3" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e2" e2="DDI-PubMed.22515360.s10.e4" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e2" e2="DDI-PubMed.22515360.s10.e5" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e2" e2="DDI-PubMed.22515360.s10.e6" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e3" e2="DDI-PubMed.22515360.s10.e3" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e3" e2="DDI-PubMed.22515360.s10.e4" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e3" e2="DDI-PubMed.22515360.s10.e5" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e3" e2="DDI-PubMed.22515360.s10.e6" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e4" e2="DDI-PubMed.22515360.s10.e4" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e4" e2="DDI-PubMed.22515360.s10.e5" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e4" e2="DDI-PubMed.22515360.s10.e6" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e5" e2="DDI-PubMed.22515360.s10.e5" /><pair ddi="false" e1="DDI-PubMed.22515360.s10.e5" e2="DDI-PubMed.22515360.s10.e6" /></sentence><sentence text=" Follow-up endoscopy or urea breath test was performed 8 weeks later to assess treatment response"><entity charOffset="24-28" id="DDI-PubMed.22515360.s11.e0" text="urea" /></sentence><sentence text="" /><sentence text="The eradication rates of EAL and EAT groups were 78"><entity charOffset="33-36" id="DDI-PubMed.22515360.s13.e0" text="EAT" /><entity charOffset="25-28" id="DDI-PubMed.22515360.s13.e1" text="EAL" /><pair ddi="false" e1="DDI-PubMed.22515360.s13.e1" e2="DDI-PubMed.22515360.s13.e1" /><pair ddi="false" e1="DDI-PubMed.22515360.s13.e1" e2="DDI-PubMed.22515360.s13.e0" /></sentence><sentence text="1 versus 75" /><sentence text="0%, p = " /><sentence text="676 (in intention-to-treat analysis) and 80" /><sentence text="3 versus 80%, p = " /><sentence text="0964 (per-protocol analysis)" /><sentence text=" Both groups exhibited similar drug compliance (95" /><sentence text="3 vs 96" /><sentence text="9%, p = " /><sentence text="952) but more adverse events in the EAT group (6"><entity charOffset="36-38" id="DDI-PubMed.22515360.s22.e0" text="EAT" /></sentence><sentence text="3 vs 12" /><sentence text="5%, p = " /><sentence text="225)" /><sentence text="" /><sentence text="Despite low in vitro drug resistances to amoxicillin and tetracycline, the efficacy of 14-day EAT regimens attained an unacceptable report card of 75% eradication rates in intention-to-treat analysis and was not even superior to the 7-day EAL regimen"><entity charOffset="41-52" id="DDI-PubMed.22515360.s27.e0" text="amoxicillin" /><entity charOffset="57-69" id="DDI-PubMed.22515360.s27.e1" text="tetracycline" /><entity charOffset="94-105" id="DDI-PubMed.22515360.s27.e2" text="EAT" /><entity charOffset="239-250" id="DDI-PubMed.22515360.s27.e3" text="EAL" /><pair ddi="false" e1="DDI-PubMed.22515360.s27.e0" e2="DDI-PubMed.22515360.s27.e0" /><pair ddi="false" e1="DDI-PubMed.22515360.s27.e0" e2="DDI-PubMed.22515360.s27.e1" /><pair ddi="false" e1="DDI-PubMed.22515360.s27.e0" e2="DDI-PubMed.22515360.s27.e2" /><pair ddi="false" e1="DDI-PubMed.22515360.s27.e0" e2="DDI-PubMed.22515360.s27.e3" /><pair ddi="false" e1="DDI-PubMed.22515360.s27.e1" e2="DDI-PubMed.22515360.s27.e1" /><pair ddi="false" e1="DDI-PubMed.22515360.s27.e1" e2="DDI-PubMed.22515360.s27.e2" /><pair ddi="false" e1="DDI-PubMed.22515360.s27.e1" e2="DDI-PubMed.22515360.s27.e3" /><pair ddi="false" e1="DDI-PubMed.22515360.s27.e2" e2="DDI-PubMed.22515360.s27.e2" /><pair ddi="false" e1="DDI-PubMed.22515360.s27.e2" e2="DDI-PubMed.22515360.s27.e3" /></sentence><sentence text=" Drug-drug interaction between combined antibiotics should be considered other than in vivo drug resistances" /><sentence text="" /></document>